SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for MYRIAD GENETICS INC (MYGN) (CIK 0000899923) (MYGN) — Mar 25, 2014

MYRIAD GENETICS INC (MYGN) (CIK 0000899923)
Date: March 25, 2014 · CIK: 0000899923 · Accession: 0000000000-14-014870

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-26642

Date
June 30, 2013
Author
/s/ Joel Parker
Form
UPLOAD
Company
MYRIAD GENETICS INC (MYGN) (CIK 0000899923)

Letter

March 25 , 201 4 Via E -mail Mr. James S. Evans Chief Financial Officer Myriad Genetics, Inc . 320 Wakara Way Salt Lake City, UT 84108

Re: Myriad Genetics, Inc . Form 10-K for the Fiscal Year Ended June 30, 2013 Filed August 14, 2013 File No. 000-26642

Dear Mr. Evans :

We have completed our review of your filing. We remind you that our comment or change s to disclosure in response to our comment do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any pers on under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information in the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Joel Parker

Show Raw Text
March 25 , 201 4

Via E -mail
Mr. James S. Evans
Chief Financial Officer
Myriad Genetics, Inc .
320 Wakara Way
Salt Lake City, UT 84108

Re:  Myriad Genetics, Inc .
Form 10-K for the Fiscal Year Ended June  30, 2013
Filed August 14, 2013
  File No.  000-26642

Dear Mr. Evans :

We have completed our review of your filing.   We remind you that our comment or
change s to disclosure in response to our comment do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any pers on under the
federal securities laws of the United States.   We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information in the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Joel Parker

Joel Parker
Accounting Branch Chief